Page last updated: 2024-11-01

nilvadipine and Aging

nilvadipine has been researched along with Aging in 4 studies

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

ExcerptRelevanceReference
"The drug is equally effective in treating hypertension in elderly and younger patients and does not appear to adversely affect glucose or lipid metabolism."6.39Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. ( Brogden, RN; McTavish, D, 1995)
"nilvadipine or terazosin was administered for 2 weeks in a randomized crossover manner."2.69Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke. ( Abe, I; Fujishima, M; Hasuo, Y; Nishino, Y; Onaka, U; Setoguchi, M, 1998)
"The drug is equally effective in treating hypertension in elderly and younger patients and does not appear to adversely affect glucose or lipid metabolism."2.39Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. ( Brogden, RN; McTavish, D, 1995)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Himeda, T1
Kanbara, S1
Oki, C1
Kato, H1
Araki, T1
Shimamoto, H1
Shimamoto, Y1
Brogden, RN1
McTavish, D1
Setoguchi, M1
Onaka, U1
Abe, I1
Hasuo, Y1
Nishino, Y1
Fujishima, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340]Phase 3511 participants (Actual)Interventional2013-04-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for nilvadipine and Aging

ArticleYear
Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
    Drugs & aging, 1995, Volume: 6, Issue:2

    Topics: Aging; Angina Pectoris; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular

1995

Trials

2 trials available for nilvadipine and Aging

ArticleYear
Nilvadipine increases cerebral blood flow in elderly hypertensives: comparison with nifedipine.
    Journal of human hypertension, 1995, Volume: 9, Issue:4

    Topics: Aged; Aging; Antihypertensive Agents; Aorta; Cerebrovascular Circulation; Compliance; Cross-Over Stu

1995
Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 1998, Volume: 20, Issue:7

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aging; Blood Pressure Monitoring, Ambulatory;

1998

Other Studies

1 other study available for nilvadipine and Aging

ArticleYear
Effects of chronic administration with nilvadipine against immunohistochemical changes related to aging in the mouse hippocampus.
    Metabolic brain disease, 2005, Volume: 20, Issue:2

    Topics: Aging; Animals; Calcium Channel Blockers; Cell Death; Cell Proliferation; Cytoprotection; Dose-Respo

2005